Navigation Links
R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
Date:7/21/2009

TOKYO, July 21 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 17 that as a phase 1 clinical study on the new compound RK-023 that is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed.

The phase 1 clinical study of RK-023 consisted of a patch test (open, closed, photo-patch test), single-dose study and 5-day repeated-dose study. Since no serious adverse event occurred in each test, RK-023 seems to hardly cause any safety problem in the human body.

As the first step, patch tests were conducted to obtain data on skin irritation. Using RK-023 preparation and a placebo, the tests were conducted on 20 healthy adult males by the following 3 methods and the results were evaluated.

    (1) Open patch test: Open patch dressing to the forearm skin for 48 hours
    (2) Closed patch test: Closed patch dressing to the back skin for 48 hours
    (3) Photo-patch test: Closed patch dressing to the back skin for 24 hours,
        followed by UVA irradiation

No adverse event occurred and the resulting irritation was negligible in each test.

As the next step, single and 5-day repeated applications of RK-023 preparation to the scalp were conducted by a randomized, placebo-controlled, double blind method to evaluate the safety and pharmacokinetics of the drug. In the single-dose study, 2 ml of RK-023 preparation was applied to the vertex region of 6 out of 9 healthy adult males and a placebo to that of the remaining 3 subjects. The applied drug was spread widely covering the vertex region in order to investigate the safety in the entire body and scalp. No serious adverse event occurred. After application of the drug, blood and urine were collected in the lapse of time to determine drug concentrations. However, the drug concentration was below the quantification li
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
4. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
7. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
8. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Reportlinker.com announces that a new market research ... Innovations in Wound Care Devices and ... Introduction Wound ... range of sizes, shapes, stages, and types ...
... 2012 /PRNewswire-iReach/ -- Global Information, Inc. (GII) is ... Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts ... The Insulin Delivery Devices Market is ... $11 Billion by 2017 GlobalData estimated ...
Cached Medicine Technology:Innovations in Wound Care Devices and Dressings 2Innovations in Wound Care Devices and Dressings 3Innovations in Wound Care Devices and Dressings 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:1/23/2015)... Phoenix, AZ (PRWEB) January 23, 2015 Hastings ... personal injury matters, reports a record number of legal representation ... Statistically speaking, there has been a steady rise in the ... at work and at home throughout the Valley. With that ... their accident be reviewed by an experienced law firm. Hastings ...
(Date:1/22/2015)... January 22, 2015 Liberty University has received ... program from the Council for Accreditation of Counseling ... of Liberty’s Center for Counseling & Family Studies , ... of the university’s new School of Behavioral Sciences. Prior to ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... 26 (HealthDay News) -- If you,re told that your child ... carefully consider the situation, advises an expert. "Take ... respond defensively with ,not my child., Understand that your child ... health services at Saint Joseph,s University in Philadelphia, said in ...
... high body mass index (BMI) between 9 and 12 years of ... blood insulin levels (all risk factors for developing heart disease) by ... bmj.com today. Reassuringly, say the authors, children with ... reach adolescence have better heart disease risk profiles than those who ...
... Mammals began to grow much larger after dinosaurs became extinct ... international team of researchers analyzed the fossils of major groups ... size increased from a maximum of about 10 kilograms (22 ... maximum of 17 tonnes (18.7 U.S. tons) after dinosaurs became ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... who took a popular class of heartburn drugs while ... heightened risk of birth defects, a large Danish study ... inhibitors (PPIs), include blockbusters such as Prilosec (omeprazole), Prevacid ...
... outbreaks in refugee camps in earthquake-wracked Haiti, a group ... University, and the International Vaccine Institute (IVI) have urged ... cholera vaccines for future humanitarian use. "The ... stockpile of several million doses of cholera vaccine would ...
... Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- There,s encouraging ... babies. Children whose mothers took certain anti-seizure medications while breast-feeding ... 3, a new study finds. The multi-center study looked ... common antiepileptic drugs, and found no difference in IQ levels ...
Cached Medicine News:Health News:Parents of Bullies Urged to Open Lines of Communication 2Health News:A high BMI in childhood linked to greater heart disease risk in adolescence 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 2Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 4Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 2Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 3
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: